Comparative Pharmacology
Head-to-head clinical analysis: MIVACRON versus VECURONIUM BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIVACRON versus VECURONIUM BROMIDE.
MIVACRON vs VECURONIUM BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mivacurium is a bis-benzylisoquinoline neuromuscular blocking agent that acts as a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, leading to muscle paralysis.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine binding and muscle contraction.
0.15-0.2 mg/kg IV bolus for intubation; maintenance infusion 9-10 mcg/kg/min
IV bolus: 0.08-0.1 mg/kg for intubation; maintenance: 0.01-0.015 mg/kg every 12-15 minutes as needed or continuous infusion 0.05-0.1 mg/kg/hour.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 minutes; clinically, rapid clearance via plasma cholinesterase results in short duration.
Terminal elimination half-life: 1.2-1.9 hours (65-115 minutes). Clinically, recovery from neuromuscular blockade is faster than with pancuronium; prolonged in renal and hepatic impairment.
Primarily renal (approximately 80-90% as unchanged drug and metabolites) and biliary (small fraction, <20% as metabolites).
Primarily renal (40-60% unchanged in urine within 24 hours); biliary/fecal elimination accounts for <20%. Approximately 10-20% as 3-desacetylvecuronium (active metabolite) in urine.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker